Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups

Amblard, Iris; Mercier, Frédéric; Bartlett, David L.; Ahrendt, Steven A.; Lee, K.W.; Zeh, Herbert J.; Levine, Edward A.; Baratti, Dario; Deraco, Marcello; Piso, Pompiliu; Morris, David L.; Rau, Beate; Tentes, Antonios-Apostolos; Tuech, Jean‐Jacques; Quénet, François; Akaishi, Eduardo Hiroshi; Pocard, M; Yonemura, Yutaka; Lorimier, G.; Delroeux, Delphine; Villeneuve, Laurent; Gléhen, Olivier; Passot, Guillaume; Abba, J.; Abboud, Karine; Alyami, Mohammad; Arvieux, C.; Bakrin, N.; Bereder, Jean Marc; Bouzard, D.; Brigand, Cécile; Carrère, Sébastien; Dumont, F; Eveno, Clarisse; Facy, Olivier; Guyon, Frédéric; Kianmanesh, Réza; Dico, R. Lo; Marchal, Frédéric; Mariani, Pascale; Méeus, Pierre; Msika, Simon; Ortega‐Deballon, Pablo; Paquette, Brice; Peyrat, Patrice; Pirrò, N.; Porcheron, J.; Rat, Patrick; Sgarbură, Olivia; Thibaudeau, Emilie; Zinzindohoué, Franck; Baik, Seung Hyuk; Bhatt, A.; Cachin, P.; Ceelen, Wim; Hingh, Ignace de; Simone, Michele De; Dubé, Pierre; Edwards, R.P.; Franko, Jan; González-Bayón, L.; Gushchin, Vadim; Holtzman, Matthew P.; Hsieh, Meng‐Che; Kecmanović, Dragutin; Lehmann, Kuno; Liu, Y.; Mehta, Sanket; O’Dwyer, Sarah T; Orsevigo, E.; Pande, Pankaj; Park, E.J.; Pingpank, James F.; Rajan, Firoz; Sardi, Armando; Sidéris, Lucas; Sommariva, Antonio; Spiliotis, John; Sugarbaker, Paul H.; Teo, Melissa Ching Ching; Yarema, Roman; Younan, Rami; Zaveri, Shabber

doi:10.1016/j.ejso.2018.04.023

Cited by 21 publications

(17 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GC 18,19 or GS, 32 or triplet chemotherapy with gemcitabine, cisplatin, and S‐1 17 are promising preoperative chemotherapy, and postoperative therapy with capecitabine 33 or S‐1 34 is also promising. Moreover, hyperthermic intraperitoneal chemotherapy could be a choice for patients with CY+ at risk of developing peritoneal metastasis 35 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The impact of peritoneal lavage cytology in biliary tract cancer (KHBO1701): Kansai Hepato‐Biliary Oncology Group

et al. 2020

View full text Add to dashboard Cite

Background Only few studies in literature have analyzed the clinical effects of peritoneal lavage status in biliary tract cancers. Aim We aimed to assess the effect of cytology‐positive peritoneal lavage on survival for patients with biliary tract cancer who underwent curative resection. Methods The KHBO1701 study was a multi‐institutional retrospective study that assessed the clinical effects of peritoneal lavage cytology in biliary tract cancers. Using clinicopathological data from 11 Japanese institutions, we compared long‐term outcomes between patients with cytology‐positive and cytology‐negative peritoneal lavage. Results Of 169 patients who underwent curative resection, 164 were cytology‐negative, and five were cytology‐positive. The incidence of portal invasion and preoperative carbohydrate antigen 19‐9 levels were higher in the cytology‐positive group than in the cytology‐negative group. The incidence of peritoneal metastatic recurrence was also higher, and overall survival tended to be worse in the cytology‐positive group. In contrast, recurrence‐free survival was similar between the cytology‐negative and cytology‐positive groups. Conclusions The positive status of peritoneal lavage cytology could moderately affect the survival of patients with biliary tract cancers. Given that surgical resection is the only curative treatment option, it may be acceptable to resect biliary tract cancers without other non‐curative factors, regardless of peritoneal lavage cytology status.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Moreover, hyperthermic intraperitoneal chemotherapy could be a choice for patients with CY+ at risk of developing peritoneal metastasis. 35 …”

Section: Discussionmentioning

confidence: 99%

The impact of peritoneal lavage cytology in biliary tract cancer (KHBO1701): Kansai Hepato‐Biliary Oncology Group

et al. 2020

View full text Add to dashboard Cite

show abstract

“…According to the variables analyzed, the candidates who benefit most from CRS and HIPEC are young patients, with good functional status, peritoneal carcinomatosis due to gallbladder carcinoma, low PCI and susceptible to complete cytoreduction. More than 50% of patients in both groups had a progression at 12 months and the median progression-free survival was not different in both groups, 9.3 months for the chemotherapy group versus 9.3 months for the CRS group and HIPEC with a p-value of 0.479 [12].…”

Section: Discussionmentioning

confidence: 85%

Peritoneal Metastasis of Cholangiocarcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy at the Instituto Nacional de Cancerología, Colombia

Hernandez

Restrepo

Mora

2020

Cureus

View full text Add to dashboard Cite

Cholangiocarcinoma is a low-frequency neoplasm of onset with a poor prognosis. Peritoneal carcinomatosis is the most frequent site of metastasis with a standard palliative chemotherapy treatment. In the present article, we describe the case of a 35-year-old woman with peritoneal carcinomatosis secondary to an intrahepatic cholangiocarcinoma who was treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) as a nonstandard therapeutic method. The patient has disease-free survival of 12 months with very good quality of life. The treatment of peritoneal metastasis from cholangiocarcinoma by CRS and HIPEC is feasible and could proportion better survival to these patients compared to systemic palliative chemotherapy. These therapeutic modalities can complement each other.

show abstract

“…Another retrospective multicenter study evaluated patients with peritoneal metastasis from biliary carcinoma and compared survival outcomes of CRS and HIPEC with palliative chemotherapy. They suggested that CRS and HIPEC may offer survival benefit comparing to palliative chemotherapy in highly selected patients [ 23 ].…”

Section: Discussionmentioning

confidence: 99%

A Unique Presentation of Metastatic Gallbladder Carcinoma

Tian

Luu

Carpenter

et al. 2021

Case Reports in Surgery

View full text Add to dashboard Cite

Gallbladder carcinoma can be challenging to diagnose and treat and usually leads to poor outcome, due to its aggressive nature and the nonspecific clinical presentation at early stage. We describe an interesting case of a 60-year-old female who presented with stage 3 appendiceal carcinoma after appendectomy was performed outside hospital. Further imaging workup demonstrated enlarged ovarian cysts and porcelain gallbladder. Upon exploration, she was found to have carcinomatosis and we proceeded with cytoreductive surgery (CRS) and hyperthermic intraperitoneal therapy (HIPEC). Final pathology demonstrated carcinoma from gallbladder primary.

show abstract

Cytoreductive surgery and HIPEC improve survival compared to palliative chemotherapy for biliary carcinoma with peritoneal metastasis: A multi-institutional cohort from PSOGI and BIG RENAPE groups

Cited by 21 publications

References 14 publications

The impact of peritoneal lavage cytology in biliary tract cancer (KHBO1701): Kansai Hepato‐Biliary Oncology Group

The impact of peritoneal lavage cytology in biliary tract cancer (KHBO1701): Kansai Hepato‐Biliary Oncology Group

Peritoneal Metastasis of Cholangiocarcinoma Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy at the Instituto Nacional de Cancerología, Colombia

A Unique Presentation of Metastatic Gallbladder Carcinoma

Contact Info

Product

Resources

About